Navigation Links
Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
Date:1/30/2008

- 4Q EPS Grows 21.8% to $0.72 on 19.8% Revenue Growth -

PRINCETON, N.J., Jan. 30 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today reported earnings for its fourth quarter ended December 31, 2007 of $0.78 per diluted share and full-year EPS of $2.71; both periods include a $0.06 per share gain from the sale of its centralized ECG business. Excluding the gain on sale, earnings were $0.72 per diluted share in the fourth quarter, representing 21.8% year-over-year EPS growth, and $2.65 per diluted share for the full-year, representing annual EPS growth of 20.5% over 2006 EPS of $2.20 (which excludes a $0.04 per share tax gain from the 2006 results).

"I congratulate the entire Covance team for another year of outstanding achievement for our clients and shareholders. Increasing levels of client satisfaction led to strong repeat work resulting in more than $500 million in net orders for the quarter and a 20.6% growth in our backlog to $2.7 billion," said Joe Herring, Chairman and Chief Executive Officer. "In the fourth quarter, revenue growth was robust at 19.8% and operating margins remained solid at 14.8%. Performance reflected strong demand for both our early- and late-stage development service offerings. In addition, we significantly reduced our DSO to 36 days, the lowest level in more than 5 years, helping to drive strong free cash flow for the quarter and the year.

"In 2007, our capital expenditures exceeded $200 million, with a substantial portion allocated to investments in capacity expansion and IT infrastructure to support our future growth. Covance's consistent history of generating strong returns on capital combined with the increasing demand for our drug development services, leads us to increase strategic capital investment in 2008 in order to support our long-term growth opportunity.

"Our ongoing success with productivity enhancements made a significant contribution again in 2007, as evidenced by a 4.3% increas
'/>"/>

SOURCE Covance Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2007 Financial Results Conference Call
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 Research and ... Liquid Analyzer, Gas Analyzer, and Gas Chromatograph Market by ... Region - Global Trends & Forecast to 2013 - ... A process analyzer is a process analytical instrument that ... It has redefined the way by which companies carry ...
(Date:9/29/2014)... Transparency Market Research, in its report titled ‘Peptide ... Application - Cancer, Metabolic, CVS, CNS & others, by ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... market was worth US$14.1 billion in 2011 and is ... 8.7% CAGR. , The two main types of peptide ...
(Date:9/29/2014)... Mass. , Sept. 29, 2014  Atlas Venture, ... life sciences and technology innovation, today announced that ... Epizyme (NASDAQ: EPZM ), is joining the ... October 1, 2014. At Atlas, Rhodes will ... groundbreaking companies. He brings an accomplished record in company ...
(Date:9/29/2014)... Sept. 29, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: ... and commercializes proprietary technologies and products for advanced microarray ... Peter Winkley to Chairman of the Board of ... Ricks will continue to serve as a Director on ... the Company.  "We are very pleased ...
Breaking Biology Technology:Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2SQI Diagnostics Announces New Chairman of Board of Directors 2
... 29 Tutogen Medical, Inc.,(Amex: TTG ), a ... (allograft) and animal (xenograft) tissue, announced today,that Guy L. ... the Roth Capital Partners New York Investor Conference on,Thursday, ... conference is,being held at The Westin NY at Times ...
... N.Y., Aug. 29 Emisphere,Technologies, Inc. (Nasdaq: ... been appointed to the position of Chief Financial ... CFO and Interim Chief Executive Officer,of Astralis, Ltd., ... Michael V. Novinski, President and Chief Executive Officer. ...
... PHRM ) today announced that the U.S. ... designation for oral Azacitidine in the,treatment of Myelodysplastic ... to facilitate the development and,expedite the review of ... or,life-threatening conditions and that demonstrate the potential to ...
Cached Biology Technology:Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6
(Date:9/29/2014)... article published online in Behavioral Brain Research ... brain as a result of chronic alcohol exposure that ... , Clinical assessments and research indicate that individuals with ... This can occur when people are actively drinking, when ... abstaining. , "Sleep-wake disturbances can last for months, ...
(Date:9/29/2014)... when the supercontinent of Pangea was starting to break up ... kinds of reptiles called phytosaurs and rauisuchids were at the ... the two top predators didn,t interact much as the former ... land. But those ideas are changing, thanks largely to the ... online in September in the German journal Naturwissenschaften ...
(Date:9/29/2014)... Growing Demand From Huge ... Security Concerns Continue to Propel Biometrics Market in ... is one of the fastest growing biometrics markets ... majorly in various government projects such as National ... biometrics dominates the country,s biometrics market, with other ...
Breaking Biology News(10 mins):Tooth buried in bone shows prehistoric predators tangled across land, sea 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3
... flat. Even the flattest of basement membranes has topography; ... , Unlike the princess kept awake by the ... cultured on a substrate deliberately printed with nanoscale ... of Wisconsin–Madison. , The researchers used soft ...
... been stopped early due to preliminary results indicating that ... HIV during heterosexual intercourse by 53 percent. , The ... 12 to review the interim data. Based on the ... trial and recommended that all men enrolled in the ...
... Give or take a few dozen trillions, a human adult ... roundworm has exactly 959 cells. , Yet we have ... University, who has been exploring two “highly conserved? cell-signaling pathways ... we have a lot of common enemies, particularly soil-borne ...
Cached Biology News:Embryonic stem cells do better on bumpy nanoscale mattress 2Male circumcision reduces HIV risk, study stopped early 2Male circumcision reduces HIV risk, study stopped early 3Worms produce surprise insight into human fever 2
...
... The new IKATUBE ULTRA TURRAX Tube Disperser System ... homogenizing system. It offers a cleaner, safer, and ... system processes sample volumes from 2 to 15 ... type, researchers can choose one of 4 different ...
...
... Triple-angle light scattering detector for ... digital signal processing hardware for two ... UV detectors. Also contains an analog ... interfacing to strip chart recorders. Includes ...
Biology Products: